Long Focus Capital Management LLC Has $44.93 Million Position in Insmed Incorporated (NASDAQ:INSM)

Long Focus Capital Management LLC lifted its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 650,800 shares of the biopharmaceutical company's stock after buying an additional 21,900 shares during the period. Insmed comprises 1.5% of Long Focus Capital Management LLC's holdings, making the stock its 13th largest position. Long Focus Capital Management LLC owned approximately 0.36% of Insmed worth $44,931,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of INSM. National Bank of Canada FI boosted its position in Insmed by 9.7% during the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 147 shares during the last quarter. Abel Hall LLC boosted its holdings in shares of Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock valued at $230,000 after buying an additional 151 shares during the last quarter. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares in the last quarter. M&T Bank Corp increased its holdings in Insmed by 5.6% during the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock worth $217,000 after buying an additional 166 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock worth $244,000 after acquiring an additional 183 shares in the last quarter.

Insmed Price Performance

Insmed stock opened at $71.24 on Wednesday. The firm has a market cap of $12.95 billion, a PE ratio of -12.74 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock's fifty day moving average price is $74.99 and its two-hundred day moving average price is $73.58. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. As a group, research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Truist Financial upped their target price on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Guggenheim reaffirmed a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Wells Fargo & Company increased their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares in the company, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the company's stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. This represents a 2.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 471,797 shares of company stock worth $37,621,239. 3.00% of the stock is currently owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.